50jili voucher code

50jili voucher code Jake Auchincloss sells State Street Corporation stockThe Remarkable Collapse of Iran’s Powerful AlliancesCARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.Jones, Mellott help Montana State run over Montana 34-11

Broadcom Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Quarterly DividendUS wholesale inflation accelerated in November in sign that some price pressures remain elevated WASHINGTON (AP) — Wholesale costs in the United States picked up sharply last month, signaling that price pressures are still evident in the economy even though inflation has tumbled from the peak levels it hit more than two years ago. The producer price index — which tracks inflation before it reaches consumers — rose 0.4% last month from October, up from 0.3% the month before. Measured from 12 months earlier, wholesale prices climbed 3% in November, the sharpest year-over-year rise since February 2023. Higher food prices helped fuel the November wholesale inflation reading, which was higher than economists had expected. Senate begins final push to expand Social Security benefits for millions of people WASHINGTON (AP) — The Senate is pushing toward a vote on legislation that would provide full Social Security benefits to millions of people. Senate Majority Leader Chuck Schumer began the process on Thursday for a final vote on the bill, known as the Social Security Fairness Act. It would eliminate policies that currently limit Social Security payouts for roughly 2.8 million people. The legislation has passed the House. The bill would add more strain on the Social Security Trust funds, which are already estimated to be unable to pay out full benefits beginning in 2035. The measure would add an estimated $195 billion to federal deficits over 10 years, according to the Congressional Budget Office. IRS recovers $4.7 billion in back taxes and braces for cuts with Trump and GOP in power WASHINGTON (AP) — IRS leadership on Thursday announced that the agency has recovered $4.7 billion in back taxes and proceeds from a variety of crimes. The announcement comes under the backdrop of a promised reckoning from Republicans who will hold a majority over both chambers of the next Congress and have long called for rescinding the tens of billions of dollars in funding provided to the agency by Democrats. IRS Commissioner Danny Werfel said improvements made to the agency will help the incoming administration and new Republican majority congress achieve its goals of administering an extension of the 2017 Tax Cuts and Jobs Act. From a 10-year-old to a Muppet to a president-elect, NYSE bell-ringers range from famous to obscure The first guest invited to ring the bell at the New York Stock Exchange in 1956 wasn’t a company executive, a politician or a well-known celebrity. It was a 10-year-old boy, Leonard Ross, who received the honor by winning a television quiz show.Since then, business titans, political giants and global film stars have all been among those ringing the opening bell at the NYSE. Ronald Reagan rang the bell as president in 1985. Billionaire businessman and former New York City Mayor Michael Bloomberg and Hollywood star Robert Downey Jr. - have also rung the bell. The list includes famous Muppets: Miss Piggy was once a bell ringer. Trump is named Time's Person of the Year and rings the New York Stock Exchange's opening bell NEW YORK (AP) — President-elect Donald Trump rang the opening bell at the New York Stock Exchange after being recognized by Time magazine as its person of the year. The honors Thursday for the businessman-turned-politician are a measure of Trump’s remarkable comeback from an ostracized former president who refused to accept his election loss four years ago to a president-elect who won the White House decisively in November. At the stock exchange, Trump was accompanied by his wife, Melania Trump, daughters Ivanka and Tiffany and Vice President-elect JD Vance. Trump grinned as people chanted “USA” before he opened the trading day and raised his fist. Ontario to restrict electricity exports to US and bar American-made alcohol if Trump tariffs applied TORONTO (AP) — A senior official in Canada’s most populous province says that Ontario could bar American-made alcohol and restrict electricity to three U.S. states if President-elect Donald Trump imposes sweeping tariffs on all Canadian products. The states are Michigan, New York and Minnesota. An official in Ontario Premier Doug Ford’s government said Thursday that it's contemplating restricting Ontario's liquor control board from buying American-made alcohol. Ontario is also considering restricting exports of Canadian critical minerals required for electric vehicle batteries. ECB cuts rates a quarter point amid concerns of tepid growth, impact of Trump trade policies FRANKFURT, Germany (AP) — The European Central Bank is cutting interest rates by a quarter percentage point amid signs of weakening growth and concern about the impact of political chaos in France and the possibility of new U.S. import tariffs. The bank’s rate-setting committee made the decision Thursday at its skyscraper headquarters in Frankfurt to lower the benchmark rate from 3.25% to 3%. Lower rates should support growth amid signs that the post-pandemic recovery is slowing in the 20 countries that use the euro currency and concerns that U.S. President-Elect Donald Trump might impose new tariffs, or import taxes, on goods imported to the US after he is inaugurated Jan. 20. YouTube TV is hiking its monthly price, again. Here's what to know NEW YORK (AP) — Are you a YouTube TV subscriber? Your monthly bills are about to get more expensive again. YouTube has announced that it’s upping the price of its streaming service’s base plan by $10 — citing rising content costs and other investments. The new $82.99 per month price tag will go into effect starting Jan. 13 for existing subscribers, and immediately for new customers who sign up going forward. YouTube TV has rolled out a series of price hikes over the years. When launched back in 2017, the going price of its streaming package was $35 a month. By 2019, that fee rose to $50 — and has climbed higher and higher since. Head of the Federal Aviation Administration to resign, allowing Trump to pick his successor The head of the Federal Aviation Administration says he will step down next month to let President-elect Donald Trump name his choice to lead the agency. Mike Whitaker announced his pending resignation in a message to FAA employees on Thursday. Since taking the helm at the FAA in October 2023, Whitaker has dealt with challenges that include a surge in close calls between planes, a shortage of air traffic controllers and antiquated equipment. He has led a tougher enforcement policy against Boeing since a panel blew off a jetliner in January. The White House is cracking down on overdraft fees NEW YORK (AP) — The Consumer Financial Protection Bureau said Thursday it's capping overdraft fees at $5 with a rule set to take effect in October 2025, if it isn't overturned by Congress or altered under a Trump administration. President Joe Biden had called the fees, which can be as high as $35, “exploitative,” while the banking industry has lobbied extensively to keep the existing fee structures in place.

6 stocks that Fools have been buying!

Red Bluff beats Foothill 21-10, will play for first section title in 25 years

NoneDemocrat Defends Bill That Would Check Cabinet Picks' Foreign Dealings

The Washington Department of Fish and Wildlife (WDFW) is gearing up for the lowland trout lakes program. They will be planting hatchery trout from now through spring in many local lakes, and the season kicks off with the Black Friday trout opener. For over a decade the popular program has aimed to get families and friends out together for a day of fighting fish, instead of fighting the holiday shopping crowds. State-wide there will be 24 lakes stocked with “jumbo” rainbow trout before Nov. 29, ranging up to 17 inches in length, with some of tipping the scales at three pounds. 65,000 trout will be stocked out, mostly in the western part of the state. Stacie Kelsey of the WDFW Inland Fishes Program reports that the same lakes will soon be stocked in Region 5 as in recent years. Each of them will receive 2,000 of the jumbo-sized trout. “Those are the best lakes for the area, and they seem to produce well,” Kelsey said. She said the program seems to get more popular every year. “We do get a lot of good feedback about it,” she added. Two lakes in Clark County will be stocked for the event: Klineline Pond, in Vancouver’s Salmon Creek Park, and Battle Ground Lake, in Battle Ground Lake State Park. Kress Lake in Cowlitz County will also receive 2,000 jumbo rainbow trout. Two Lewis County lakes will also be stocked, the Fort Borst Park Pond, and the South Lewis County Park Pond. In Klickitat County Rowland Lake will be stocked. In addition to the Black Friday stockings, many lowland trout lakes will also be planted with “catchable” rainbow trout. These fish run from 10 to 12 inches. In the months to come, plenty of trophy sized brood trout will also be stocked out, providing anglers a shot at trout from five to 10 pounds. In Clark County, Klineline Pond has already been stocked with 2,000 catchable trout. Kelsey reports that in both Battle Ground Lake, and Klineline Pond, the trout seem to prefer bait to artificial lures. And, while Berkley Power Bait has always been the most popular offering, the trout already stocked in Klineline Pond are showing a preference for a different bait right now. “For some reason the bite on Power Bait has been kind of slacking off there,” she said. “Now it’s the Berkley Trout Nuggets that are catching fish.” She added that some anglers have been fishing with a combination of a worm tipped with a salmon egg. Klineline Pond has excellent bank access, while Battle Ground is a good lake for small boats, and there is a fishing pier there as well. The two lakes in Lewis County that get the Black Friday stockings tend to fish very well, too, according to Kelsey. “Fort Borst Park is very popular with families and kids,” she said. “It’s got pretty good shore access all the way around it.” The South Lewis County Park Pond also has very good shore access, and there is a boat launch and a fishing pier. In the Columbia River Gorge, Rowland Lake is very popular on Black Friday, and it is a larger lake with a boat launch and good bank access. Lures and bait both work well here, and Kelsey reports that these fish are very aggressive. “Rowland is really popular, and every year it’s just such a good lake for the Black Friday fishery,” she said. The trout at Rowland seem to take just about every kind of offering, including trolling small plugs in 2 or 2.5 inches, casting or trolling spinners and spoons, or fishing bait below a bobber, or on the bottom. A few other local lakes have already been stocked with catchable trout, including Lacamas Lake near Camas, which has already received 4,000 catchable rainbow trout. Also, Icehouse Lake near the Washington end of The Bridge of the Gods near Stevenson received 2,000 catchable rainbow trout on Nov. 13. Icehouse Lake has been fishing very well with spinners recently, but over time the trout will switch to preferring bait. Kelsey also mentioned that just ahead of Christmas, Sacajawea Lake in Longview will once again receive a strong stocking of jumbo trout that will rival the big rainbows stocked out for Black Friday. This fishery has also become very popular in recent years. The enthusiasm around the Black Friday stocking program is another reason that trout fishing is the most popular kind of fishing in Washington state. “I think it’s going to be another great year,” said Kelsey, “and we just encourage people to get out and have fun with their families. It’s a great time to take a kid fishing, or a parent fishing.” Buzz Ramsey’s winter trout tips Few people get more excited about this fishery than local fishing legend Buzz Ramsey, who was one of the original promoters of the program. Listed here are some of his tips for getting the most out of this event. 1. Sleep in and enjoy the late-day bite. “A guy can start early, but it seems like the best bite starts about 9 or 10 o’clock,” Ramsey said. “The water is cold, just a slight rise in temperatures as the day progresses, even a fraction of a degree, seems to turn those fish on. I’ve seen it time and time again.” He reports that the best fishing seems to be mid-day. 2. Smaller baits work better in the cold water. “The fish are not real aggressive in the cold water,” he said. “Powerbait is the overall favorite, but the trout will take a smaller bait better. For the best success, try using a small enough hook and just big enough bait that it floats off the bottom, so the cruising trout can find it. Too big a hook and it will sink to the bottom. It can get bit that way, but it’s not as effective.” He suggests a size 18 treble hook, and just enough bait to float it off the bottom. Using a free-sliding sinker and some slack in the line will also help. The fish can grab the bait and swim and off taking the bait deeper while not feeling that weight on the line. “Set the hook,” said Ramsey. “Don’t forget that.” 3. Troll with small plugs, spinners, or spoons. “I have caught them on everything, a 2.5 flatfish, a little Maglip, or the Spinfish in the 2.0 or 2.5 size,” he said. “I stuff the Spinfish with tuna and troll them behind a small lake troll flasher. I have also caught them trolling Rooster Tails, and the Thomas Minnow. He reminds anglers that using some scent on your bait can increase the bites, and tipping your spinner with a small bit of Berkley Trout Worm, or some other attractant can increase your success. 4. When it is warm and windy, fish the windward shore. “If you get some afternoon sun, those fish will come into the shallows, not real shallow, but they will move into that warm water,” Ramsey said. “Also, if you get a west wind on a sunny day, it blows that warm water onto the east end of the lake. It can be good to fish the windy end of the lake when that happens. It can be really good then.” ———— For more information: Check the WDFW trout stocking report at: https://wdfw.wa.gov/fishing/reports/stocking/trout-plants ———— For more on the Black Friday fishery, here is the WDFW blog page: https://wdfw.medium.com/score-a-holiday-deal-by-heading-to-a-lake-for-black-friday-trout-fishing-fun-7d93c0ce8933

WEST PALM BEACH, Fla. (AP) — President-elect Donald Trump said Saturday he intends to nominate real estate developer Charles Kushner , father of Trump’s son-in-law Jared Kushner, to serve as ambassador to France. Trump made the announcement in a Truth Social post, calling Charles Kushner “a tremendous business leader, philanthropist, & dealmaker." Javascript is required for you to be able to read premium content. Please enable it in your browser settings.The AP Top 25 college football poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . MOREHEAD, Ky. (AP) — Isaiah Smith ran for a career-high 205 yards on 31 carries and scored a touchdown and San Diego beat Morehead State 37-14 in a season-ending contest for both teams on Saturday. Grant Sergent threw for 184 yards and two touchdowns for San Diego (8-3, 6-2 Pioneer Football League) which ended the season with a four-game win streak and winners of six of seven. The Toreros finished in sole possession of second place in the PFL behind Drake (7-1), which clinched the league outright with a 49-10 win over Stetson on Saturday. Drake beat San Diego 30-28 on a walk-off field goal on Sept. 28 in Des Moines, Iowa. Bryce Patterson threw for 133 yards and a touchdown and James Louis ran for a touchdown for the Eagles (7-5, 5-3). ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP collegebasketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketball

Fox News Flash top sports headlines are here. Check out what's clicking on Foxnews.com. A wild brawl ensued after Saturday's Michigan-Ohio State game in Columbus. After Michigan pulled off the unlikely victory , members of the team attempted to plant a UM flag at midfield, a big no-no in college football. The Buckeyes took offense and did what they could to stop it. And that led to violence and police resorting to pepper spray to break things up. CLICK HERE FOR MORE SPORTS COVERAGE ON FOXNEWS.COM Head coach Sherrone Moore, left, of the Michigan Wolverines shakes hands with head coach Ryan Day of the Ohio State Buckeyes after a game at Ohio Stadium Nov. 30, 2024 in Columbus, Ohio. (Jason Mowry/Getty Images) Despite the incident turning ugly, OSU head coach Ryan Day seemed to defend his players. "I don’t know all the details, but I know these guys were looking to put a flag on our field, and we’re not going to let that happen," Day said after the game. Michigan head coach Sherrone Moore, who waved goodbye to Buckeyes fans in the crowd after the Wolverines' final stop, took the high road. Players scrum at midfield after Saturday’s game between the Ohio State Buckeyes and the Michigan Wolverines. (Imgan) OHIO STATE LOSES TO MICHIGAN FOR FOURTH STRAIGHT YEAR IN HUGE UPSET; PLAYOFF STATUS NOW UP IN THE AIR "It was emotion on both sides. It can’t happen. ... We got to handle it better," Moore said. Michigan running back Kalel Mullins, who ran for over 100 yards in the contest, said the moment was "bad for the sport," saying it was "classless" for the Buckeyes to take it to that level. "It was such a great game. You hate to see stuff like that happen after the game. Bad for the sport, bad for college football. But, at the end of the game, they gotta learn how to lose, man," Mullins said. "You can't be fighting and stuff just because you lost a game. We had 60 minutes and four quarters to do all that fighting, and now people want to talk and fight. That's wrong. It's bad for the game — classless in my opinion — and people want to be better." Michigan Wolverines and Ohio State Buckeyes players fight after a game at Ohio Stadium in Columbus Saturday, Nov. 30, 2024. Michigan won 13-10. (Imagn) CLICK HERE TO GET THE FOX NEWS APP It was the fourth year in a row Michigan defeated Ohio State after the Buckeyes had won 15 of 16 meetings. Follow Fox News Digital’s sports coverage on X , and subscribe to the Fox News Sports Huddle newsletter .